Skip to content
Therapy But Better – Lifestyle
Author:
Rafael Holdings, Inc.
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
September 30, 2026
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
June 11, 2026
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
June 10, 2026
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
April 22, 2026